Grail Stock

grail.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $2.02B

GRAIL is a healthcare company specializing in early cancer detection by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to developed a multi-cancer early detection blood test.

Register To Buy and Sell Shares

For more details on financing and valuation for Grail, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Grail’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Grail.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Gautam Kollu
Chief Commercial Officer
Matthew Young
Chief Financial Officer & Chief Operating Officer
Aaron Freidin
Chief Financial Officer

Board Members

Brook Byers Ph.D
Maykin Ho Ph.D
Robert Nelsen
ARCH Venture Partners
Xiangmin Cui Ph.D
Decheng Capital
Catherine Friedman
Kaye Foster
William Rastetter Ph.D
Richard Klausner MD

News Highlights

Point32Health to Offer Grail Cancer Early Detection Test Under Pilot Program
The health plan provider will make testing available to its own employees, followed by its approximately 2.2 million commercial members.
Caris Life Sciences Facing FTC Lawsuit After Resisting Subpoena in Illumina, Grail Antitrust Case
Caris said it has already provided materials to Illumina and should not have to indulge a "fishing expedition for irrelevant, highly sensitive details."
European Commission Adopts Interim Measure to Hold Grail Separate From Illumina
The measures are legally binding for both Illumina and Grail, and compliance with them will be monitored by a trustee to be approved by the commission.
Updated on: May 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.